uracil has been researched along with Renal Insufficiency, Chronic in 14 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alogliptin improves steroid-induced hyperglycemia by decrease of glucagon levels through an increase in plasma GLP-1 levels." | 7.80 | Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels. ( Fujigaki, Y; Fujikura, T; Isobe, S; Iwakura, T; Kato, A; Naito, Y; Ohashi, N; Ono, M; Sakao, Y; Tsuji, N; Tsuji, T; Yasuda, H, 2014) |
| "We conducted an observational prospective study, on 232 patients with chronic kidney disease, undergoing treatment with paritaprevir/ombitasvir/ritonavir and dasabuvir, for chronic hepatitis C infection - genotype 1b." | 3.96 | Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease. ( Iliescu, EL; Mercan-Stanciu, A; Toma, L, 2020) |
| "Alogliptin improves steroid-induced hyperglycemia by decrease of glucagon levels through an increase in plasma GLP-1 levels." | 3.80 | Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels. ( Fujigaki, Y; Fujikura, T; Isobe, S; Iwakura, T; Kato, A; Naito, Y; Ohashi, N; Ono, M; Sakao, Y; Tsuji, N; Tsuji, T; Yasuda, H, 2014) |
| "7%): 4 due to severe adverse events (including 3 deaths) and 1 patient´s decision." | 1.51 | Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study. ( Ahumada, A; Aldamiz-Echevarría, T; Baliellas, C; Barril, G; Benlloch, S; Bonet, L; Carmona, I; Castaño, MA; Castro, Á; de Álvaro, C; de Los Santos, I; Delgado, M; Devesa-Medina, MJ; García-Buey, L; García-Samaniego, J; Gea-Rodríguez, F; González-Parra, E; Gutiérrez, ML; Jiménez-Pérez, M; Laguno, M; Londoño, MC; Losa, JE; Mallolas, J; Manzanares, A; Martín-Granizo, I; Montero-Alonso, M; Montes, ML; Morán-Sánchez, S; Morano, L; Muñoz-Gómez, R; Navascués, CA; Polo-Lorduy, B; Riveiro-Barciela, M; Rivero, A; Roget, M; Serra, MÁ, 2019) |
| "In the interferon era, the treatment of hepatitis C virus (HCV) infection in patients on haemodialysis (HD) was limited due to the significant number of treatment-related adverse events (AEs)." | 1.51 | Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia. ( Arias, M; Belmar, L; González, LN; Laguno, M; Llovet, LP; Londoño, MC; Maduell, F; Mallolas, J; Martínez-Rebollar, M; Ojeda, R; Rodas, L; Rossi, F; Ugalde, J, 2019) |
| " RBV was dosed by physician discretion between 200 mg weekly and 200 mg daily." | 1.48 | High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease. ( Afghani, AA; Alghamdi, AS; Alghamdi, MN; AlMousa, A; Alswat, K; AlZanbagi, A; Aseeri, M; Assiri, AM; Babatin, MA; Sanai, FM, 2018) |
| "We recruited 36 CKD patients with type 2 diabetes." | 1.40 | Effects of alogliptin in chronic kidney disease patients with type 2 diabetes. ( Mugishima, K; Murasawa, T; Ohno, D; Otsuka, T; Otsuka, Y; Sakai, Y; Sumi, Y; Suzuki, A; Tsuruoka, S, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (92.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Londoño, MC | 2 |
| Riveiro-Barciela, M | 1 |
| Ahumada, A | 1 |
| Muñoz-Gómez, R | 1 |
| Roget, M | 1 |
| Devesa-Medina, MJ | 1 |
| Serra, MÁ | 1 |
| Navascués, CA | 1 |
| Baliellas, C | 1 |
| Aldamiz-Echevarría, T | 1 |
| Gutiérrez, ML | 1 |
| Polo-Lorduy, B | 1 |
| Carmona, I | 1 |
| Benlloch, S | 1 |
| Bonet, L | 1 |
| García-Samaniego, J | 1 |
| Jiménez-Pérez, M | 1 |
| Morán-Sánchez, S | 1 |
| Castro, Á | 1 |
| Delgado, M | 1 |
| Gea-Rodríguez, F | 1 |
| Martín-Granizo, I | 1 |
| Montes, ML | 1 |
| Morano, L | 1 |
| Castaño, MA | 1 |
| de Los Santos, I | 1 |
| Laguno, M | 2 |
| Losa, JE | 1 |
| Montero-Alonso, M | 1 |
| Rivero, A | 1 |
| de Álvaro, C | 1 |
| Manzanares, A | 1 |
| Mallolas, J | 2 |
| Barril, G | 1 |
| González-Parra, E | 1 |
| García-Buey, L | 1 |
| Wiegand, J | 1 |
| Buggisch, P | 1 |
| Mauss, S | 1 |
| Boeker, KHW | 1 |
| Klinker, H | 1 |
| Müller, T | 1 |
| Günther, R | 1 |
| Serfert, Y | 1 |
| Manns, MP | 1 |
| Zeuzem, S | 1 |
| Berg, T | 1 |
| Hinrichsen, H | 1 |
| C-Registry, GH | 1 |
| Iliescu, EL | 1 |
| Mercan-Stanciu, A | 1 |
| Toma, L | 1 |
| Sanai, FM | 1 |
| Alghamdi, AS | 1 |
| Afghani, AA | 1 |
| Alswat, K | 1 |
| AlZanbagi, A | 1 |
| Alghamdi, MN | 1 |
| AlMousa, A | 1 |
| Aseeri, M | 1 |
| Assiri, AM | 1 |
| Babatin, MA | 1 |
| Abdel-Razek, W | 1 |
| Waked, I | 1 |
| Maduell, F | 1 |
| Belmar, L | 1 |
| Ugalde, J | 1 |
| Martínez-Rebollar, M | 1 |
| Ojeda, R | 1 |
| Arias, M | 1 |
| Rodas, L | 1 |
| Rossi, F | 1 |
| Llovet, LP | 1 |
| González, LN | 1 |
| Fabrizi, F | 1 |
| Negro, F | 1 |
| Bondin, M | 1 |
| Cacoub, P | 1 |
| Örmeci, N | 1 |
| Sezgin, O | 1 |
| Karaali, R | 1 |
| Aygen, B | 1 |
| Turan, D | 1 |
| Yaras, S | 1 |
| Erdem, İ | 1 |
| Yildiz, O | 1 |
| Karakaya, F | 1 |
| Ateş, K | 1 |
| Asiller, ÖÖ | 1 |
| Charbonnel, B | 1 |
| Schweizer, A | 1 |
| Dejager, S | 1 |
| Nakamura, Y | 1 |
| Inagaki, M | 1 |
| Shimizu, T | 1 |
| Fujita, K | 1 |
| Inoue, M | 1 |
| Gotoh, H | 1 |
| Oguchi, K | 1 |
| Goto, Y | 1 |
| Sakai, Y | 1 |
| Suzuki, A | 1 |
| Mugishima, K | 1 |
| Sumi, Y | 1 |
| Otsuka, Y | 1 |
| Otsuka, T | 1 |
| Ohno, D | 1 |
| Murasawa, T | 1 |
| Tsuruoka, S | 1 |
| Ohashi, N | 1 |
| Tsuji, N | 1 |
| Naito, Y | 1 |
| Iwakura, T | 1 |
| Isobe, S | 1 |
| Ono, M | 1 |
| Fujikura, T | 1 |
| Tsuji, T | 1 |
| Sakao, Y | 1 |
| Yasuda, H | 1 |
| Kato, A | 1 |
| Fujigaki, Y | 1 |
| Uchida, T | 1 |
| Oda, T | 1 |
| Matsubara, H | 1 |
| Watanabe, A | 1 |
| Takechi, H | 1 |
| Oshima, N | 1 |
| Sakurai, Y | 1 |
| Kumagai, H | 1 |
| Flynn, C | 1 |
| Bakris, GL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Occult Hepatitis C Virus Infection In Hemodialysis Patients Who Achieved A Sustained Virological Response To Directly Acting Antiviral Drugs: Is It A Concern ?[NCT04719338] | 30 participants (Actual) | Interventional | 2021-03-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for uracil and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Expert opinion on the management of renal manifestations of chronic HCV infection.
Topics: 2-Naphthylamine; Amides; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Benzofur | 2018 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-P | 2013 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dise | 2013 |
1 trial available for uracil and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug-Related Side Effect | 2013 |
10 other studies available for uracil and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Ther | 2019 |
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Car | 2019 |
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Drug Thera | 2020 |
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug | 2018 |
Editorial: is sofosbuvir-based therapy suitable for patients with advanced chronic kidney disease?
Topics: 2-Naphthylamine; Anilides; Benzimidazoles; Carbamates; Cyclopropanes; Fluorenes; Humans; Lactams, Ma | 2018 |
Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia.
Topics: 2-Naphthylamine; Anemia; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Darbepoetin alfa; Fe | 2019 |
Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropan | 2019 |
Effects of alogliptin in chronic kidney disease patients with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypo | 2014 |
Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels.
Topics: Aged; Asian People; Body Mass Index; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; | 2014 |
Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis.
Topics: Actins; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blood Urea Nitrogen; Calci | 2017 |